Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia

Bone Marrow Transplantation volume 37, pages 997–1001 (2006)Cite this article

Abstract

Recombinant urate oxidase (rasburicase) lowers uric acid levels rapidly to very low levels at the labeled dose of 0.15–0.2 mg/kg daily for 5 days. Our past experience showed that a lower dose (3 mg) lowered uric acid levels sufficiently in most patients. A retrospective review was conducted to determine the effect of a fixed 3 mg dose of rasburicase in 43 adult patients with cancer undergoing hematopoietic stem cell transplantation or receiving chemotherapy who had elevated or rising uric acid levels (6.4–16.8 mg/dl; median 9.6). Six patients received a second dose of rasburicase (3 mg in four patients and 1.5 mg in two patients) 24 h later. Patients received allopurinol, adequate hydration, as well as other supportive therapy as required. Uric acid levels declined by 6–95% (median 43%) within the first 24 h after rasburicase administration, and levels at 48 h were 9–91% (median 65%) lower than the baseline levels. Serum creatinine changed by ⩽10% in 21 patients, increased by >10% in four patients and decreased by >10% in 18 patients. No significant renal dysfunction developed in any of the patients. We conclude that rasburicase is effective in lowering uric acid levels at a fixed dose of 3 mg, which is much lower than the recommended dose.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ . Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546–554.

    Article  CAS  Google Scholar 

  2. Smith GW, Wright V . Allopurinol. Br J Clin Pract 1987; 41: 710–711.

    CAS  PubMed  Google Scholar 

  3. Wu XW, Lee CC, Muzny DM, Caskey CT . Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412–9416.

    Article  CAS  Google Scholar 

  4. Leach M, Parsons RM, Reilly JT, Winfield DA . Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 1998; 20: 169–172.

    Article  CAS  Google Scholar 

  5. Bayol A, Capdevielle J, Malazzi P, Buzy A, Bonnet MC, Colloc'h N et al. Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002; 36: 21–31.

    Article  CAS  Google Scholar 

  6. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998–3003.

    Article  CAS  Google Scholar 

  7. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402–4406.

    Article  CAS  Google Scholar 

  8. Lee AC, Li CH, So KT, Chan R . Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37: 1614–1617.

    Article  Google Scholar 

  9. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R . Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003; 17: 2542–2544.

    Article  CAS  Google Scholar 

  10. Trifilio S, Tallman M, Singhal S, Gordon L, Evens A, Mehta J . Low-dose recombinant urate oxidase (rasburicase) is effective in hyperuricemia. Blood (ASH Annu Meeting Abstr) 2004; 104: 3312.

    Google Scholar 

  11. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Suppl Care Cancer 2003; 11: 249–257.

    CAS  Google Scholar 

  12. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A . Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160–165.

    CAS  PubMed  Google Scholar 

  13. Schrag D . The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317–319.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, Northwestern Memorial Hospital, Chicago, IL, USA

    S Trifilio & J Pi

  2. Division of Hematology/Oncology, Hematopoietic Stem Cell Transplant Program, The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    S Trifilio, L Gordon, S Singhal, M Tallman, A Evens, K Rashid, M Fishman, K Masino & J Mehta

Authors
  1. S Trifilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Evens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Masino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Pi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trifilio, S., Gordon, L., Singhal, S. et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 37, 997–1001 (2006). https://doi.org/10.1038/sj.bmt.1705379

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705379

Keywords

This article is cited by

Search

Advanced search

Quick links